2-异丙基吡啶 | 644-98-4

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-异丙基吡啶
• 中文别名: 異丙吡啶
• 英文名称: 2-isopropylpyridine
• 英文别名: 2-(1-methyl ethyl)pyridine；2-propan-2-ylpyridine
• CAS: 644-98-4
• 化学式: C₈H₁₁N
• mdl: MFCD00047438
• 分子量: 121.182
• InChiKey: PFYPDUUXDADWKC-UHFFFAOYSA-N

物化性质

• 熔点：
  -141°C
• 沸点：
  160℃
• 密度：
  1.45
• 闪点：
  23℃
• LogP：
  2.206 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 安全说明：
  S26,S36/37/39
• 海关编码：
  2933399090
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 包装等级：
  III
• 危险类别：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险品运输编号：
  1993
• 危险性描述：
  H225,H315,H319,H335
• 储存条件：
  室温下应保存于惰性气体中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Isopropylpyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Isopropylpyridine
CAS number: 644-98-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H11N
Molecular weight: 121.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  2-乙基吡啶	2-Ethylpyridine	100-71-0	C7H9N	107.155
  6-(羟甲基-乙基)吡啶	2-(pyridin-2-yl)propan-1-ol	68888-19-7	C8H11NO	137.181
  2,6-二叔丁基吡啶	2,6-di-tert-butyl-pyridine	585-48-8	C13H21N	191.316
  2-吡啶-2-丙醇	2-(pyridine-2-yl)propan-2-ol	37988-38-8	C8H11NO	137.181
  2-异丙烯基吡啶	2-isopropenylpyridine	6515-13-5	C8H9N	119.166
  碳酸甲丙酯	α-picoline	109-06-8	C6H7N	93.1283

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  2-叔丁基吡啶	2-tert-butylpyridine	5944-41-2	C9H13N	135.209
  ——	2-(pyridin-2-yl)propan-1-amine	851670-39-8	C8H12N2	136.197
  ——	2-sec-butylpyridine	6304-23-0	C9H13N	135.209
  2-(3-乙丙基)嘧啶	2-(pentan-3-yl)pyridine	7399-50-0	C10H15N	149.236
  ——	2-isopropylpyridine	1228273-78-6	C8H11N	122.174
  2-甲基-2-吡啶-2-基-丙醛	2-methyl-2-pyridin-2-yl-propionaldehyde	23649-43-6	C9H11NO	149.192
  ——	2-(tert-pentyl)pyridine	35109-17-2	C10H15N	149.236
  ——	2-isopropylpyridine N-oxide	65257-53-6	C8H11NO	137.181
  ——	2-methyl-2-(2-pyridyl)-1-propanol	34995-30-7	C9H13NO	151.208
  ——	2-(1-chloro-1-methyl-ethyl)-pyridine	6581-08-4	C8H10ClN	155.627

反应信息

• 作为反应物：
  描述：

  2-异丙基吡啶 在 rhodium(III) oxide 、 氢气 作用下， 以 2,2,2-三氟乙醇 为溶剂， 40.0 ℃ 、500.01 kPa 条件下， 以99%的产率得到2-isopropylpiperidine
  参考文献：
  名称：

  在温和条件下用氧化铑催化剂氢化官能化吡啶

  摘要：

  哌啶是药物和农化化合物合成中使用最广泛的结构单元之一。吡啶的氢化是合成此类化合物的便捷方法，因为它只需要反应物、催化剂和氢源。然而，该反应对于官能化和多取代吡啶的还原仍然很困难。在这里，我们报道了使用稳定的市售铑化合物Rh 2 O 3来还原各种未保护的吡啶。该反应条件温和，底物范围广，具有实用价值。

  DOI：

  10.1039/d3ob01860a
• 作为产物：
  描述：

  2-i-C3H7-C5H4N*BH3 在 奎宁环 作用下， 以 甲苯 为溶剂， 生成 2-异丙基吡啶
  参考文献：
  名称：

  路易斯碱离核参数 NFB 及其在 MIDA-硼酸盐水解动力学分析中的应用

  摘要：

  已经测量了从广泛的路易斯碱硼烷加合物中置换 BH 3的奎宁环动力学。这些速率的参数化使得能够开发出离核量表 (NF B )，以量化和预测一系列其他路易斯碱基的离去基团能力。在多个系列 R' 3– n R n X (X = P, N; R' = 芳基, 烷基) 中观察到的可加性允许制定相关的取代基参数 ( n f PB , n f AB )，提供了一种方法计算N F B一系列路易斯碱基的值远远超出了实验得出的值。通过取代基参数n f PB与一系列烷基和芳基 MIDA 硼酸盐在中性条件下的水解速率的相关性，探索了核离性参数的效用。这允许鉴定具有接近反应中心的杂原子的 MIDA 硼酸盐，显示出不寻常的动力学不稳定性或水解稳定性。

  DOI：

  10.1021/acs.joc.1c02729

文献信息

• Iridium(III)-Catalyzed Direct Arylation of C–H Bonds with Diaryliodonium Salts
  作者：Pan Gao、Wei Guo、Jingjing Xue、Yue Zhao、Yu Yuan、Yuanzhi Xia、Zhuangzhi Shi

  DOI：10.1021/jacs.5b06758

  日期：2015.9.30

  arylation of complex compounds. Mechanistic studies by density functional theory calculations suggested that the sp(3) C-H activation was realized by a triflate-involved concerted metalation-deprotonation process, and the following oxidation of Ir(III) to Ir(V) is the most favorable when a bistriflimide is contained in the diaryliodonium salt. Calculations indicated that both steps are enabled by initial anion

  通过开发一种新的 Ir(III) 催化的 CC 交叉偶联，已经建立了一种将酮肟、含氮杂环、各种芳烃和烯烃中的 sp(2) 和 sp(3) CH 键直接芳基化的通用方法。该芳基化的关键取决于适当的催化剂选择和使用二芳基碘鎓Triflate Salts作为偶联伴侣。这种转化具有良好的官能团兼容性，可以作为复杂化合物后期 CH 芳基化的有力合成工具。通过密度泛函理论计算的机理研究表明 sp(3) CH 活化是通过三氟甲磺酸酯参与的协同金属化-去质子化过程实现的，当双氟甲磺酰亚胺包含在二芳基碘鎓盐中。
• HETEROBICYCLIC COMPOUNDS
  申请人：Amgen Inc.

  公开号：US20130225552A1

  公开（公告）日：2013-08-29

  Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

  Formula (I)的杂环化合物： 或其药用可接受的盐、互变异构体或立体异构体，如规范中所定义，并含有它们的组合物，以及制备这种化合物的方法。本文还提供了通过抑制PDE10来治疗由此可治疗的疾病或疾病的方法，如肥胖症、非胰岛素依赖型糖尿病、精神分裂症、躁郁症、强迫症、亨廷顿病等。
• Triazolone derivatives
  申请人：Clark Richard

  公开号：US20080015199A1

  公开（公告）日：2008-01-17

  A Compound represented by the following general formula (1), salts thereof or hydrates of the foregoing is a novel compound useful for treatment and/or prevention of diseases associated with thrombus formation, and which is safer with suitable physicochemical stability. [wherein R 1a , R 1b , R 1c and R 1d each independently represent hydrogen, etc.; R 2 represents optionally substituted phenyl, etc.; R 3 represents optionally substituted C6-10 aryl, etc.; and Z 1 and Z 2 each independently represent hydrogen]

  以下一般式（1）表示的化合物，其盐或上述化合物的水合物是一种新型化合物，可用于治疗和/或预防与血栓形成相关的疾病，并且具有适当的物理化学稳定性，更安全。 [其中R1a，R1b，R1c和R1d分别独立表示氢等；R2表示可选择取代的苯基等；R3表示可选择取代的C6-10芳基等；Z1和Z2分别独立表示氢]
• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GLAXOSMITHKLINE LLC

  公开号：US20150152108A1

  公开（公告）日：2015-06-04

  The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

  本发明涉及新型取代桥式脲化合物，相应的相关类似物，药物组合物以及其使用方法。本发明的抑制素调节化合物可用于延长细胞寿命，并治疗和/或预防各种疾病和疾病，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块疾病、炎症、癌症和/或潮红有关的疾病或疾病，以及那些会受益于增加线粒体活性的疾病或疾病。本发明还涉及包含抑制素调节化合物与另一治疗剂组合的组合物。
• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。

表征谱图